Athenex, Inc. (ATNX)
| Market Cap | 1.04B |
| Revenue (ttm) | 156.94M |
| Net Income (ttm) | -118.41M |
| Shares Out | 83.71M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $11.11 |
| Previous Close | $11.66 |
| Change ($) | -0.55 |
| Change (%) | -4.72% |
| Day's Open | 11.60 |
| Day's Range | 11.07 - 11.63 |
| Day's Volume | 475,887 |
| 52-Week Range | 5.71 - 15.52 |
BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...
BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...
Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.
BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...
BUFFALO, N.Y., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel thera...
BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therap...
Athenex (ATNX) delivered earnings and revenue surprises of 4.35% and 81.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer
Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
BUFFALO, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapi...
BUFFALO, N.Y. and CHICAGO, Oct. 9, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. Athenex’s first T cell therapy product cleared to advance to the first stage of...
The company announced the pricing of a public offering of common stock.
BUFFALO, N.Y., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...
BUFFALO, N.Y., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...
The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.
The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021.
Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
The company announced good news regarding one of its leading pipeline candidates.
FDA grants Priority Review and sets PDUFA target action date of February 28, 2021
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2020 Results - Earnings Call Transcript
Athenex (ATNX) delivered earnings and revenue surprises of -32.26% and 89.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BUFFALO, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel thera...
Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track
Pharmaceutical industry veteran with significant oncology clinical development expertise appointed to Board Pharmaceutical industry veteran with significant oncology clinical development exper...
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BUFFALO, N.Y., July 27, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel thera...
BUFFALO, N.Y., June 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel thera...
BUFFALO, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and com...
BUFFALO, N.Y. and CHICAGO, June 13, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of nove...
Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Shares of Athenex (NASDAQ:ATNX) fell 4.8% after the company reported Q1 results. Quarterly Results Earnings per share were up 54.72% year over year to ($0.24), which missed the estimate of ($0...
Athenex (ATNX) delivered earnings and revenue surprises of -14.29% and 46.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).
BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...
BUFFALO, N.Y., April 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...
BUFFALO, N.Y., March 13, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...
PDUFA date of December 30, 2020 PDUFA date of December 30, 2020
Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BUFFALO, N.Y., March 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ther...
Athenex (ATNX) delivered earnings and revenue surprises of 44.00% and 185.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BUFFALO, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Today, Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex, Inc. (Nasdaq: ATNX), informed shareholders he received a notice of a...
Athenex, Inc. (ATNX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Athenex: Compelling Overall Survival Advantage For Oral Paclitaxel, Revaluation In Progress
About ATNX
Athenex, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Ora... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jun 14, 2017 |
| CEO Johnson Lau | Employees 574 |
| Stock Exchange NASDAQ | Ticker Symbol ATNX |
Financial Performance
In 2019, Athenex's revenue was $101.23 million, an increase of 13.61% compared to the previous year's $89.10 million. Losses were -$123.75 million, 5.37% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for Athenex stock is "Buy." The 12-month stock price forecast is 27.41, which is an increase of 146.71% from the latest price.